UroGen Pharma Ltd
URGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.11B
Close$
$-30.06
172.9% downside
Current Fair Value
172.9% downsideOvervalued by 172.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.11 Billion |
|---|---|
| Enterprise Value | $2.22 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.19 |
| Beta | 1.58 |
| Outstanding Shares | 50,380,112 |
Return
| Return on Equity | 73.75% |
|---|---|
| Return on Assets | -38.65% |
| Return on Invested Capital | -39.34% |
Valuation & Multiples
| P/E Ratio | -21.84 |
|---|---|
| PEG | 30.65 |
| Price to Sales | 13.74 |
| Price to Book Ratio | -13.74 |
| Enterprise Value to Revenue | 11.78 |
| Enterprise Value to EBIT | -29.65 |
| Enterprise Value to Net Income | -23 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | -1.48 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.27
Average shareholder expectationRevenue Estimate
$63.55 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.10
Average shareholder expectationRevenue Estimate
$90.58 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.5671▼ 19.42% |
|---|---|
| Total Calls | 259,400▲ 14.68% |
| Total Puts | 147,100▼ 14.58% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 84.47%▼ 8.07% |
|---|---|
| Total Invested | $1.57B▲ 87.42% |
| Investors Holding | 199▲ 20.00% |
ESG Score
No data
About UroGen Pharma Ltd
CEO: Elizabeth Barrett